ASSAY OF NUCLEOSIDES IN SMALL-CELL CARCINOMA OF THE LUNG

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$50,000.00
Award Year:
1987
Program:
SBIR
Phase:
Phase I
Contract:
n/a
Agency Tracking Number:
7141
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
Imbic Corpon
Po Box 7539, Columbia, MO, 65205
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
JOHN E MCENTIRE PHD
(314) 874-2481
Business Contact:
() -
Research Institution:
n/a
Abstract
SEVERAL INVESTIGATORS HAVE IMPLICATED MODIFIED RIBONUCLEOSIDES, PRESUMABLY MODIFICATION PRODUCTS FROM TRANSFER RIBONUCLEIC ACIDS (TRNAS), AS POTENTIAL BIOLOGICAL MARKERS FOR CANCER. ELEVATED LEVELS OF THESE MOLECULES HAVE BEEN QUANTITATED IN THE SERUM OR URINE OF CANCER PATIENTS BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY-ULTRAVIOLET (HPLC-UV) OR IMMUNOASSAY. IN THIS PROPOSAL, IMBIC CORPORATION WILL DEMONSTRATE THE FEASIBILITY OF PREPARING ANTIBODIES TO TWO COMMON MODIFIED NUCLEOSIDES AND THE DEVELOPMENT OF AN IMMUNOASSAY FOR THEIR EASY QUANTITATION. ADDITIONALLY, THE LEVELS OF 30 MODIFIED NUCLEOSIDES WILL BE DETERMINED IN THE SERUM FROM LUNG CANCER PATIENTS AND NORMAL CONTROLS. THESE DATA WILL BE SUBJECTED TO PATTERN RECOGNITION ANALYSIS TO DEVELOP A PROFILE OF SELECTED SERUM-MODIFIED NUCLEOSIDE CONCENTRATIONS THAT CAN DEFINE BIOLOGICAL MARKERS FOR LUNG CANCER. AN IMMUNOASSAY DIAGNOSTIC KIT WILL BE DEVELOPED TO DETECT THESE BIOMARKERS WITH HIGH SENSITIVITY AND SPECIFICITY.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government